NEU neuren pharmaceuticals limited

It should but even then this is all the back off the comments...

  1. 2,540 Posts.
    lightbulb Created with Sketch. 691
    It should but even then this is all the back off the comments from the Acadia CEO and we don't even have the full year results, nor the guidance for year ahead yet. I get that the market is disappointed but the 30% increase in salesforce and the European expansion doesn't track against the view that Daybue will peak in sales very shortly. Nuplazid has its own challenges but continues to grow year on year and they haven't marketed that outside the US. They clearly have a lot of faith in Daybue but the market just doesn't see it at all.

    I don't like the strategy putting doubt out there in the presentation regarding Daybue but not actually fully ripping the band-aid off. They ought to do one or the other. Either not comment on it until Q4 results and guidance is ready, or do the whole lot at the JPM update and bring things forward. I really don't get why they would provide an update with vague details, so the market can continue to assume the worst.
    Last edited by htae39: 15/01/25
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$13.31
Change
0.770(6.14%)
Mkt cap ! $1.655B
Open High Low Value Volume
$12.96 $14.00 $12.91 $19.76M 1.453M

Buyers (Bids)

No. Vol. Price($)
1 3000 $13.30
 

Sellers (Offers)

Price($) Vol. No.
$13.33 3716 1
View Market Depth
Last trade - 16.10pm 26/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.